Pinned Tweet
LT position PART 1
Portfolio Positions acquired: $RNA $DAWN $SLNO $NARI $BPMC $MYOV base:0x9bba915f036158582c20b51113b925f243a1a1a1 $KRTX $HZNP $PRVB $ISEE $BLU $CTIC $FSTX $ICVX $LVGO $STML base:0x4e6c9f48f73e54ee5f3ab7e2992b2d733d0d0b07 $CMRX $RLYP $ITCI $KVUE
Tech positions: In order
$AMZN $META $NVDA $MSFT $SOFI $GOOGL $RDDT $MELI $APP $RKLB $INTC $IREN $NBIS $CRDO $AAOI $BE $AXON $MDB
Biotech positions: $VKTX $CYTK $ARDX $HROW $MDGL $CRVS $ABVX $TMDX $RVMD $NKTR $CELC $AVR
Pharmdca retweeted
$NBIS $149’s to almost $162’s. Nice intraday reversal so far..
SEHAJDEEP SINGH ने क्या गाया! 😱 | Sufi Vibes MAGIC! | Sa Re Ga Ma Pa 202... youtu.be/nWNjmpErHAM?is=eRcM… via @YouTube
No words
Musk showing typical X crowd behavior. Pump your companies and bash competitors.
Musk very vocal when discussing companies, he sees as overvalued, strategically weak, or politically aligned against his views, while simultaneously promoting a highly optimistic narrative around his own businesses such as Tesla, SpaceX, xAI, and X.
$NU BUY THE FEAR.
1) Political fear is often temporary BUT Fundamentals are not. Simple. Ignore election headlines but focus on customer growth, lending and profitability.
2) Brazil's banking market remains highly concentrated. $NU has grown to roughly 139 million customers across Brazil, Mexico and being one of the largest digital banking platforms. In fact, company continues to add millions of customers each quarter.
3) After Brazil, Mexico could be seen as the next growth engine. A massive opportunity as company recently expanding its banking infrastructure there.
4) Net income exceeded $1 Billion for the first time, up 49% year-over-year. Return on equity has almost hit 33%.
Conclusion- Company's growth has been during Lula administration so this selloff after his win makes no sense. In fact, it offers a compelling buying opportunity for long term investors.
In the end, do your due diligence as always. My DD tells me to execute and add this panic driven fear as the underlying business keeps executing and that's all what matters for investors like me. Rest is noise.
Be well.
Pharmdca retweeted
$NU Monness, Crespi, Hardt Initiation, Buy, PT $20
The firm told buyers they get to buy into a macro dislocation tied to the Lula/Bolsonaro runoff, and argued that regardless of who wins the Brazilian presidency, this is a roughly 30% ROE franchise trading at about 13x its FY27E EPS of $1.18, which sits 2% above the Street, with its FY28E estimate 5% above the Street. It said credit is seasoning better than the system, that Copom easing helps borrowers more than net interest income, that Mexico now lends as a bank, and that Monzo is off the table.
Pharmdca retweeted
ANTHROPIC IPO REPORTEDLY ON TRACK FOR NOVEMBER
Anthropic is reportedly preparing to file its S-1 registration at 9 a.m. ET Monday, with an IPO potentially taking place November 19–20, according to Fox Business.
Semiconductor stocks moved higher following the report, reflecting improved sentiment toward AI-related equities.
The key takeaway: A successful Anthropic IPO could provide a major test of investor appetite for AI valuations amid growing concerns over infrastructure spending and financing costs.
Pharmdca retweeted
Counterpoint Research expects DRAM demand from humanoid robots to surge 20x by 2030, from around 8,300 terabits in 2026 to 172,000 terabits.
The firm also expects memory per robot to more than double, from 19GB today to 39GB by 2030.
The humanoid robotics conversation has largely centered on which robot maker will win.
But the companies supplying the motion systems underneath may matter just as much, regardless of which platform comes out on top.
Actuators, the motors, reducers, sensors, and controllers that turn AI commands into physical movement, are the single largest cost driver in humanoid hardware, and every robot needs dozens of them.
Could the actuator supply chain be one of the most overlooked opportunities in physical AI?
Join KraneShares CIO @ahern_brendan, Senior Investment Strategist Derek Yan, CFA, and Max Chen of Worldline Capital for a webinar on the actuator bottleneck and how $TORK and $KOID seek to capture the physical AI opportunity at different levels of the stack.
Register: kraneshares.com/webinars/the…
TORK: kraneshares.com/etf/tork/
KOID: kraneshares.com/etf/koid/
Pharmdca retweeted
$NVDA, $AMD and $AVGO have expressed nonbinding interest in buying up to $5B of $META shares combined.
$META announced plans to raise approximately $35 billion through two offerings:
> $22.5B in Class A common stock through forward sale agreements.
> $12.5B in depositary shares representing mandatory convertible preferred stock.
Interestingly, NVIDIA, AMD and Broadcom have expressed nonbinding interest in purchasing up to $5 billion of Meta shares combined.
Meta is also planning a potential $60 billion offering program for its new nonvoting Class C shares starting in Q1 2027.
Together, the plans could provide approximately $95 billion in equity financing capacity as Meta prepares to spend $135B to $145B on capital expenditures in 2026.
$VKTX 2027 will be a monumental year with huge catalysts that will finally put all bearish theories to Rest.
Q3 Earnings— Wed Oct 28 after close
Bottom line: this is all about progress print, not about revenue. What I’m looking forward to on Wednesday — what matters is enrollment pace, burn, and any 2027 color on clinical readouts.
Cash:** $502M at June 30 plus ~$547.8M net from the September raise. Close to $1 Billion cash
- **SUNRISE (oral VK2735):** launched Oct 14 — two 68-week Phase 3 trials, 560 patients each, 27.5/35/55 mg doses. Phase 2 oral hit 12.2% mean weight loss vs 1.3% placebo at 13 weeks, no plateau.
- **Oral maintenance:** study started Oct 6–7 (~195 patients), data in 2027.
- **VANQUISH (injectable):** both Phase 3s fully enrolled; completion and final data expected 2027.
- **What to listen for Wednesday:** SUNRISE enrollment pace, Color on Oral Maintenance readout, VANQUISH data-timing color, quarterly burn, any partnership hint.
Pharmdca retweeted
$TNGX could conquer all pancreatic cancer space. Not only from efficacy perspective but from mitigating Pan RAS glues toxicities. Its valuation should explode on that.
It is not just Tango data showing this fact but Investigators experience. U can see no G3 rash in the combo trial today, and half vomit rate.
Also durability of response will make big impact for pts and for RAS biotechs , including $RVMD and $ERAS.
Interestingly RVMD likely threatening with daraxonrasib supply unless TNGX cut ties with ERAS which is not happening. This is why Tango wants to run combo using Eras 0015 in MTAP WT. insurance or tango can pay for daraxonrasib supply
I think next they should combine their PRMT5 inh with PD1 ab at large scale.
Now receiving silly hypotheses just as market confused on very strong $TNGX data. Actually the WT MTAP opportunity opens massive market in PDAC and elsewhere
To be honest $RVMD clealry unhappy with $ERAS in general - doesn’t matter if market realizes that or not - and with $TNGX expanding collaboration with Eras
TNGX CEO hinted to that. But who cares ?
DDI interactions is viewed as positive for RVMD daraxonrasib adoption as it shows lousy GI AEs alone.
100 mg combo dose will cause less N/ V.
Higher efficacy is not due to higher exposure as TNGX did PK and confirmed same exposure and rash even better.
Although RVMD bulls primary debate target coverage is maximum with 300 mg and ERAS 0015 higher potency doesn’t add … ?
Everyone in RVMD who missed on TNGX is pissed off now
Pharmdca retweeted
Tigress Financial on $AVGO
We initiate coverage of Broadcom with a Buy rating and a 12-month target price of $600, as its AI infrastructure leadership, custom silicon growth, and high-margin software platform drive a powerful multi-year growth opportunity. Broadcom's leadership in custom AI silicon, high-performance networking, and enterprise infrastructure software positions it to capture expanding global technology investment. Broadcom's explosive AI semiconductor growth, expanding hyperscaler partnerships, and exceptional profitability reinforce our bullish long-term outlook. Broadcom's expanding leadership in custom AI accelerators and multigenerational hyperscaler partnerships are creating exceptional opportunities for sustained revenue and Economic Profit acceleration. Custom AI accelerator leadership positions Broadcom as an essential technology partner to the world's largest AI Developers. Accelerating AI inference and agentic computing demand expands Broadcom's multiyear infrastructure growth opportunity. High-speed networking and optical connectivity position Broadcom to capitalize on the AI networking supercycle. VMware's expanding private AI cloud platform and high-margin recurring revenue are driving higher profitability and capital efficiency. Advanced packaging, optical innovation, and expanding manufacturing capacity strengthen Broadcom's ability to scale AI growth. Cybersecurity, enterprise automation, and mission-critical software deepen Broadcom's competitive advantages and enterprise market leadership. Broadcom's accelerating AI investments, expanding cash generation, and increasing shareholder returns reinforce significant long-term value creation potential.
$BE On my Watchlist
**BE** Q3: big beat, stock sold anyway.
- Revenue **$1.24B, up 138%** vs ~$1.07B expected
- Adj EPS **$0.94** vs ~$0.69 expected
- Guidance raised for the 3rd time this year: FY revenue now $4.4–4.6B (was $3.9–4.2B), EPS $3.10–3.40
- Sridhar: hyperscaler demand is spreading "across market segments" — the AI power story is intact